Tumors as Organs: Biologically Augmenting Radiation Therapy by Inhibiting Transforming Growth Factor β Activity in Carcinomas

Seminars in Radiation Oncology

Volumn 23, Issue 4, 2013, Pages 242-251

  Du, Shisuo ^a   Barcellos Hoff, Mary Helen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER RADIOTHERAPY; HOMEOSTASIS; HUMAN; INFLAMMATION; LARGE CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DNA DAMAGE; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; RADIOBIOLOGY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84883493454     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.05.001     Document Type: Article

References (110)

1. Nakasone E., Askautrud H., Kees T., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
2. Joyce J., Pollard J. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
3. Delaney G., Jacob S., Featherstone C., et al. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104:1129-1137.
4. Shi Y., Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
5. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGF{beta} activation. J Cell Sci 2003, 116:217-224.
6. Derynck R., Akhurst R.J., Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet 2001, 29:117-129.
7. Rifkin D. Latent transforming growth factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability. J Biol Chem 2005, 280:7409-7412.
8. Kaartinen V., Voncken J.W., Shuler C., et al. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nat. Gen 1995, 11:415-421.
9. Glick A., Kulkarni A., Tennenbaum T., et al. Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci U S A 1993, 90:6076-6080.
10. Sanford L., Ormsby I., Gittenberger-de G.A., et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997, 124:2659-2670.
11. Brown P.D., Wakefield L.M., Levinson A.D., et al. Physiochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 1990, 3:35-43.
12. Barcellos-Hoff M.H: A novel redox mechanism for TGF-beta activation. Mol Biol Cell 5: 139a, 1994.
13. Barcellos-Hoff M.H. Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 1993, 53:3880-3886.
14. Barcellos-Hoff M.H., Dix T.A. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996, 10:1077-1083.
15. Pociask D.A., Sime P.J., Brody A.R. Asbestos-derived reactive oxygen species active TGF-β1. Lab Invest 2004, 84:1013-1023.
16. Jobling M.F., Mott J.D., Finnegan M., et al. Isoform specificity of redox-mediated TGF-β activation. Radiat Res 2006, 166:839-848.
17. Barcellos-Hoff M.H., Derynck R., Tsang M.L.-S., et al. Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 1994, 93:892-899.
18. Mulder K., Levine A., Hernandez X., et al. Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells. Biochem Biophys Res Commun 1988, 150:711-716.
19. Chen C., Kang Y., Siegel P., et al. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002, 110:19-32.
20. Sandhu C., Garbe J., Bhattacharya N., et al. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997, 17:2458-2467.
21. Battegay E., Raines E., Seifert R., et al. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990, 63:515-524.
22. Bruna A., Darken R., Rojo F., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007, 11:147-160.
23. Matsuyama S., Iwadate M., Kondo M., et al. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 2003, 63:7791-7798.
24. Samanta D., Gonzalez A., Nagathihalli N., et al. Smoking attenuates transforming growth factor-β-mediated tumor suppression function through downregulation of Smad3 in lung cancer. Cancer Prev Res (Phila) 2012, 5:3453-3463.
25. Park K., Kim S., Bang Y., et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A 1994, 91:8772-8776.
26. Markowitz S., Wang J., Myeroff L., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
27. Vincent F., Nagashima M., Takenoshita S., et al. Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta. Oncogene 1999, 15:117-122.
28. Derynck R., Akhurst R., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129.
29. Reiss M. Transforming growth factor-beta and cancer: A love-hate relationship. Oncol Res 1997, 9:9447-9457.
30. Massagué J. TGFbeta in cancer. Cell 2008, 134:215-230.
31. Dvorak H. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
32. Border W., Noble N. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
33. Morty R., Königshoff M., Eickelberg O. Transforming growth factor-beta signaling across ages: From distorted lung development to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009, 6:607-613.
34. Schor S., Ellis I., Jones S., et al. Migration-stimulating factor: A genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res 2003, 63:8827-8836.
35. Gaggioli C., Hooper S., Hidalgo-Carcedo C., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007, 9:1392-1400.
36. Quante M., Tu S., Tomita H., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272.
37. De Wever O., Demetter P., Mareel M., et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123:2229-2238.
38. Tuxhorn J., McAlhany S., Yang F., et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002, 62:6021-6025.
39. Rønnov-Jessen L., Petersen O. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1996, 68:696-707.
40. Chen H., Yang W., Wen Q., et al. TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM. Exp Mol Pathol 2009, 87:189-194.
41. Zhang J., Valianou M., Cheng J. Identification and characterization of the promoter of fibroblast activation protein. Front Biosci (Elite Ed) 2010, 2:1154-1163.
42. Kojima Y., Acar A., Eaton E., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 2010, 46:20009-20014.
43. Orimo A., Gupta P., Sgroi D., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
44. Elenbaas B., Weinberg R. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001, 264:169-184.
45. ten Dijke P., Arthur H. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007, 8:857-869.
46. Goumans M., Valdimarsdottir G., Itoh S., et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003, 12:817-828.
47. Oh S., Seki T., Goss K., et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000, 97:2626-2631.
48. Lebrin F., Goumans M., Jonker L., et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004, 23:4018-4028.
49. Mazzocca A., Fransvea E., Lavezzari G., et al. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009, 50:1140-1151.
50. Stearns M., Garcia F., Fudge K., et al. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999, 5:3711-3720.
51. Ananth S., Knebelmann B., Grüning W., et al. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999, 59:2210-2216.
52. Liao S., Liu J., Lin P., et al. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 2011, 17:1415-1424.
53. Kang Y., Siegel P., Shu W., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
54. Sánchez-Elsner T., Botella L., Velasco B., et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001, 276:38527-38535.
55. Song C.X.T., Gelehrter T. Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci U S A 1999, 96:11776-11781.
56. Pollard J. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
57. Hanahan D., Weinberg R. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
58. Andreu P., Johansson M., Affara N., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
59. Yang L., Pang Y., Moses H. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31:220-227.
60. Du R., Lu K., Petritsch C., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
61. Balkwill F., Coussens L. Cancer: An inflammatory link. Nature 2004, 431:405-406.
62. Bristow R., Hill R. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
63. Wahl S., Wen J., Moutsopoulos N. TGF-beta: A mobile purveyor of immune privilege. Immunol Rev 2006, 213:213-227.
64. Thomas D., Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
65. Ghiringhelli F., Ménard C., Terme M., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005, 202:1075-1085.
66. Liu C., Wang Y., Wang C., et al. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-[U+207B]/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:35-45.
67. Ruffell B., Affara N., Coussens L. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012, 33:119-126.
68. Fridlender Z., Sun J., Kim S., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
69. Lu T., Tian L., Han Y., et al. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A 2007, 104:4365-4370.
70. Wald O., Izhar U., Amir G., et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 2006, 177:6983-6990.
71. Kioi M., Vogel H., Schultz G., et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120:694-705.
72. Du S., Qiang M., Zeng Z., et al. Inactivation of kupffer cells by gadolinium chloride protects murine liver from radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2010, 76:1225-1234.
73. Ewan K.B., Henshall-Powell R.L., Ravani S.A., et al. Transforming growth factor-β1 mediates cellular response to DNA damage in situ. Cancer Res 2002, 62:5627-5631.
74. Kirshner J., Jobling M., Pajares M., et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res 2006, 66:10861-10869.
75. Abraham R.T. Checkpoint signaling: Epigenetic events sound the DNA strand-breaks alarm to the ATM protein kinase. Bioessays 2003, 25:627-630.
76. Kastan M.B., Lim D.S., Kim S.T., et al. Multiple signaling pathways involving ATM. Cold Spring Harb Symp Quant Biol 2000, 65:521-526.
77. Wiegman E.M., Blaese M.A., Loeffler H., et al. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother Oncol 2007, 83:289-295.
78. Bouquet F., Pal A., Pilones K., et al. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 2011, 17:6754-6765.
79. Hardee M., Marciscano A., Medina-Ramirez C., et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res 2012, 72:4119-4129.
80. Ahn G., Brown J. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
81. Browder T., Butterfield C., Kräling B., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
82. Paris F., Fuks Z., Kang A., et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001, 293:293-297.
83. Czarnota G., Karshafian R., Burns P., et al. Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci U S A 2012, 109:E2033-E2041.
84. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
85. Hoffman P., Mauer A., Vokes E. Lung cancer. Lancet 2000, 355:479-485.
86. Lin M., Stewart D., Spitz M., et al. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 2011, 32:1050-1056.
87. Malkoski S., Haeger S., Cleaver T., et al. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin Cancer Res 2012, 18:2173-2183.
88. Xu J., Bao Y., Liu X., et al. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma. Lung Cancer 2007, 58:36-43.
89. Zhang H., Chen X., Wang M., et al. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 2004, 10:2359-2367.
90. Kim W., Park C., Jung Y., et al. Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 1999, 9:301-306.
91. Santos A., Jung J., Aziz N., et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009, 119:3613-3625.
92. Denys H., Derycke L., Hendrix A., et al. Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett 2008, 266:263-274.
93. Kraman M., Bambrough P., Arnold J., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
94. Navab R., Strumpf D., Bandarchi B., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 2011, 108:7160-7165.
95. Hasegawa Y., Takanashi S., Kanehira Y., et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001, 91:964-971.
96. Gridelli C., Maione P., Rossi A., et al. The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. Oncologist 2007, 12:1183-1193.
97. S A., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
98. Ruffini E., A S., Filosso P., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009, 87:365-371.
99. Hiraoka K., Miyamoto M., Cho Y., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94:275-280.
100. Al-Shibli K., Donnem T., Al-Saad S., et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
101. Shimizu K., Nakata M., Hirami Y., et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010, 5:585-590.
102. Chen J., Yao P., Yuan A., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003, 9:729-737.
103. Ho C., Liao W., Wang C., et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 2008, 177:763-770.
104. Qiao X., Tullgren O., Lax I., et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003, 41:1-11.
105. Baumann F., Leukel P., Doerfelt A., et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol 2009, 11:368-380.
106. Asai K., Shioyama Y., Nakamura K., et al. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: Risk factors and dose-volume relationship. Int J Radiat Oncol Biol Phys 2012, 84:768-773.
107. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10:718-726.
108. Begg A., Stewart F., Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11:239-253.
109. Akhurst R., Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012, 11:790-811.
110. Anscher M.S., Thrasher B., Zgonjanin L., et al. Small molecular inhibitor of transforming growth factor-[beta] protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008, 71:829-837.